Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

NCT04074746 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04074746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04074746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
July 18, 2020
Completion date
September 23, 2025
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent anaplastic large cell lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent classic hodgkin lymphoma, recurrent mycosis fungoides, recurrent peripheral t-cell lymphoma, not otherwise specified, refractory anaplastic large cell lymphoma, refractory b-cell non-hodgkin lymphoma, refractory classic hodgkin lymphoma, refractory mycosis fungoides, refractory peripheral t-cell lymphoma, not otherwise specified